NASDAQ:MORF

Morphic (MORF) Stock Forecast, Price & News

$21.73

+0.72 (+3.43%)

(As of 09:46 AM ET)

Compare

Today's Range: $21.26
▼
$21.77
50-Day Range: $21.01
▼
$59.22
52-Week Range: $19.80
▼
$63.08

Volume: 120,602 shs
Average Volume: 608,131 shs
Market Capitalization: $1.04 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.71

Morphic MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 193.7% Upside
$61.71 Price Target
Short Interest: Bearish
6.76% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: -0.04
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1.50 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.83) to ($4.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

423rd out of 975 stocks

Pharmaceutical Preparations Industry

181st out of 455 stocks

3.4

Analyst's Opinion

Consensus Rating
Morphic has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $61.71, Morphic has a forecasted upside of 193.7% from its current price of $21.01.
Amount of Analyst Coverage
Morphic has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.76% of the outstanding shares of Morphic have been sold short.
Short Interest Ratio / Days to Cover
Morphic has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Morphic has recently increased by 14.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Morphic does not currently pay a dividend.
Dividend Growth
Morphic does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Morphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Morphic is -0.57.

2.2

News and Social Media Coverage

News Sentiment
Morphic has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Morphic this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for MORF on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Morphic to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,497,146.00 in company stock.
Percentage Held by Insiders
28.10% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.66% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Morphic are expected to decrease in the coming year, from ($3.83) to ($4.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Morphic is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Morphic is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Morphic has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Morphic (NASDAQ:MORF) Stock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

MORF Price History

30 days | 90 days | 365 days | Advanced Chart

MORF Stock News Headlines

October 1, 2023 | americanbankingnews.com

Morphic (NASDAQ:MORF) Shares Up 7.6%

September 30, 2023 | markets.businessinsider.com

Where Morphic Holding Stands With Analysts

October 3, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 30, 2023 | americanbankingnews.com

BMO Capital Markets Cuts Morphic (NASDAQ:MORF) Price Target to $52.00

September 29, 2023 | americanbankingnews.com

Morphic (NASDAQ:MORF) Stock Price Down 3.8% After Analyst Downgrade

September 28, 2023 | msn.com

Morphic Holding: The Price Drop Is Very Interesting

September 27, 2023 | msn.com

Morphic (NASDAQ:MORF) Resumes Slide After CEO Takes Temporary Leave

September 26, 2023 | finance.yahoo.com

Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence

October 3, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

September 26, 2023 | seekingalpha.com

Morphic cut to Neutral at BTIG citing concerns over lead asset

September 26, 2023 | americanbankingnews.com

Morphic (NASDAQ:MORF) Price Target Cut to $33.00 by Analysts at Stifel Nicolaus

September 26, 2023 | americanbankingnews.com

Morphic (NASDAQ:MORF) Downgraded by BTIG Research to "Neutral"

September 25, 2023 | nasdaq.com

Stifel Maintains Morphic Holding (MORF) Hold Recommendation

September 25, 2023 | msn.com

BTIG Downgrades Morphic Holding (MORF)

September 25, 2023 | markets.businessinsider.com

Morphic Therapeutic's Stock Plunges On Monday - Here's Why?

September 25, 2023 | bizjournals.com

Morphic Therapeutic stock nosedives on disappointing trial data

September 25, 2023 | finance.yahoo.com

The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days

September 25, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Morphic Holding (MORF), Electronic Arts (EA) and Toast Inc (TOST)

September 24, 2023 | americanbankingnews.com

Morphic (NASDAQ:MORF) Stock Price Down 5.4%

September 22, 2023 | finance.yahoo.com

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

September 9, 2023 | finance.yahoo.com

Morphic Holding Inc CFO and COO Marc Schegerin Sells 20,000 Shares

August 29, 2023 | finance.yahoo.com

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

August 9, 2023 | seekingalpha.com

Stifel cuts Morphic to hold, doesn't see it as near-term M&A target

August 9, 2023 | finance.yahoo.com

Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 7, 2023 | finance.yahoo.com

Morphic Holding, Inc.'s (NASDAQ:MORF) large institutional owners must be happy as stock continues to impress, up 4.4% over the past week

August 6, 2023 | fool.com

Morphic (NASDAQ: MORF)

August 3, 2023 | finance.yahoo.com

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023

See More Headlines

Receive MORF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter.

MORF Company Calendar

Last Earnings: 8/03/2023
Today: 10/03/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MORF
CUSIP: N/A
CIK: 1679363
Web: www.morphictx.com
Phone: (781) 996-0955
Fax: N/A
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $61.71
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +193.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,040,000.00
Net Margins: -92.38%
Pretax Margin: -1,484.46%
Return on Equity: -27.71%
Return on Assets: -26.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 41.70
Quick Ratio: 41.70

Sales & Book Value

Annual Sales: $70.81 million
Price / Sales: 14.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.06 per share
Price / Book: 2.32

Miscellaneous

Outstanding Shares: 47,920,000
Free Float: 34,457,000
Market Cap: $1.01 billion
Optionable: Not Optionable
Beta: 1.33

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Praveen P. Tipirneni M.D. (Age 55)
CEO, MD & Director
Comp: $991.33k

Dr. Bruce N. Rogers Ph.D. (Age 54)
Pres
Comp: $787.88k

Dr. Timothy A. Springer Ph.D. (Age 75)
Founder, Independent Director & Member of Scientific Advisory Board
Comp: $40k

Dr. Marc Schegerin M.B.A. (Age 47)
M.D., CFO & COO
Comp: $722.38k

Mr. Robert E. Farrell Jr. (Age 58)
CPA, CPA, Sr. VP of Fin. & Chief Accounting Officer

Dr. Blaise Lippa Ph.D.
Chief Scientific Officer

Mr. William D. DeVaul Esq. (Age 52)
Gen. Counsel & Sec.

Mr. Aaron Pelta
Sr. VP of Bus. & Corp. Devel.

Ms. Joanne Gibbons
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MORF Stock - Frequently Asked Questions

Should I buy or sell Morphic stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares.
View MORF analyst ratings or view top-rated stocks.
What is Morphic's stock price forecast for 2023?: 7 analysts have issued 1-year price objectives for Morphic's shares. Their MORF share price forecasts range from $33.00 to $80.00. On average, they predict the company's share price to reach $61.71 in the next year. This suggests a possible upside of 193.7% from the stock's current price.
View analysts price targets for MORF or view top-rated stocks among Wall Street analysts.
How have MORF shares performed in 2023?: Morphic's stock was trading at $26.75 at the beginning of the year. Since then, MORF stock has decreased by 21.5% and is now trading at $21.01.
View the best growth stocks for 2023 here.
When is Morphic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MORF earnings forecast.
How were Morphic's earnings last quarter?: Morphic Holding, Inc. (NASDAQ:MORF) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.02. Morphic had a negative trailing twelve-month return on equity of 27.71% and a negative net margin of 92.38%.
What ETFs hold Morphic's stock?: ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include Alpha Architect U.S. Quantitative Momentum ETF (QMOM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).First Trust Small Cap Growth AlphaDEX Fund (FYC).

What other stocks do shareholders of Morphic own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO).
When did Morphic IPO?: (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.
What is Morphic's stock symbol?: Morphic trades on the NASDAQ under the ticker symbol "MORF."
How do I buy shares of Morphic?: Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Morphic's stock price today?: One share of MORF stock can currently be purchased for approximately $21.01.
How much money does Morphic make?: Morphic (NASDAQ:MORF) has a market capitalization of $1.01 billion and generates $70.81 million in revenue each year. The company earns $-59,040,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.
How many employees does Morphic have?: The company employs 110 workers across the globe.
How can I contact Morphic?: Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The official website for the company is www.morphictx.com. The company can be reached via phone at (781) 996-0955.

This page (NASDAQ:MORF) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial